126
Results found
-
World NTD Day 2024: Unite. Act. Eliminate
Today, 30 January, marks World Neglected Tropical Diseases Day, one of 11 Global Health Days recognized by the World Health Organization (WHO). -
The European Medicines Agency adopts positive opinion of our treatment option for schistosomiasis in preschool-aged children
The Pediatric Praziquantel Consortium is proud to announce a new milestone: The European Medicines Agency (EMA) has adopted a positive scientific opinion of our new pediatric treatment option for preschool-aged children with schistosomiasis. -
The Pediatric Praziquantel Consortium’s regulatory approach
In December 2022, the European Medicines Agency (EMA) validated for review our regulatory application for the potential new pediatric treatment option for schistosomiasis. -
Preparing for implementation: ADOPT program update
Together with local stakeholders, the ADOPT program is developing an implementation approach tailored to local conditions in endemic countries for introducing our potential new pediatric treatment for schistosomiasis, once approved. -
Recent Consortium meetings
It’s been a busy period of meetings over the last couple of months, with the Consortium bringing together partners, collaborators, and key external stakeholders to strengthen relationships and explore new ways of working. We look back at the key events to date and their outcomes. -
Schistosomiasis: a child health development challenge
Early childhood, the period from birth to age 8, is recognized as a critical phase of intense physical and cognitive growth. Infants and children facing health challenges during this time may suffer detrimental and long-lasting health consequences. -
International Day of the African Child: Recognizing schistosomiasis as a child health development challenge
On this year’s International Day of the African Child, marked annually on 16 June, we draw attention to the fact that schistosomiasis poses a major child health development challenge. We also reinforce our commitment to providing an early childhood intervention for this preventable and treatable neglected tropical disease (NTD) most commonly found in sub-Saharan Africa. -
Putting financing for NTDs on the international agenda
Securing innovative, sustainable financing options for neglected tropical diseases (NTDs) remains a challenge, and strategies to improve aspects such as procurement are very much needed. -
Global health leaders call for accelerated investment in NTDs
The Pediatric Praziquantel Consortium was represented at the Global Neglected Tropical Diseases (NTDs) Meeting in Nagasaki on 12 May. -
World NTD Day 2023: Act now, act together, invest in NTDs
January 30 marks World NTD Day, an annual awareness day that draws attention to the inequalities of neglected tropical diseases (NTDs) like schistosomiasis. -
New milestone reached as our potential new child-friendly treatment option for schistosomiasis is validated by EMA
The Pediatric Praziquantel Consortium is pleased to announce that the European Medicines Agency (EMA) has validated for review the application for our potential new treatment option for schistosomiasis in preschool-aged children (3 months to 6 years of age). -
Bringing Stakeholders Together at International Meetings
Members of the Pediatric Praziquantel Consortium have been present at various international meetings lately presenting the work of the Consortium to research and funding partners. -
Generating Impact
Jutta Reinhard-Rupp, Chair of the Pediatric Praziquantel Consortium Board and Head of the Global Health Institute at Merck, looks back at the Consortium’s journey to date in bridging the treatment gap for preschool-age children infected with schistosomiasis. -
Our long-standing collaboration with the Global Health Innovative Technology (GHIT) Fund
The GHIT Fund invests in global research & development partnerships through a grant-making mechanism to advance Japan’s contribution to global health. Since 2014, GHIT has been supporting the Pediatric Praziquantel Consortium through five awarded grants. -
The path to submission: Development program update
Benjamin Daelken, Senior Director, Global Program Lead of the Consortium and Global Program Lead Immunology & Global Health at Merck, reflects on the progress made over the last year for the Consortium’s Development program, summarizing the key steps moving forward.